These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23767440)

  • 21. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.
    Williams RJ; Goodale LA; Shay-Fiddler MA; Gloster SP; Chang SY
    Am J Addict; 2004; 13(4):381-9. PubMed ID: 15370936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs and public policy. Poly-drug abuse: drug companies and doctors.
    Kunnes R
    Am J Orthopsychiatry; 1973 Jul; 43(4):530-2. PubMed ID: 4716670
    [No Abstract]   [Full Text] [Related]  

  • 23. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans.
    Stoops WW; Glaser PE; Fillmore MT; Rush CR
    J Psychopharmacol; 2004 Dec; 18(4):534-43. PubMed ID: 15582920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
    Aanonsen NO
    Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Ritalin ad blitz makes parents jumpy.
    Novak V
    Time; 2001 Sep; 158(10):62-3. PubMed ID: 11558351
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of cognitive enhancers: methylphenidate and analogs.
    Carlier J; Giorgetti R; Varì MR; Pirani F; Ricci G; Busardò FP
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):3-15. PubMed ID: 30657540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methamphetamine precursor regulation: are we controlling or diverting the drug problem?
    McKetin R
    Addiction; 2008 Apr; 103(4):521-3. PubMed ID: 18339098
    [No Abstract]   [Full Text] [Related]  

  • 29. Is the non-medical use of prescription stimulants a problem in Australia?
    Lucke JC; Hall WD
    Med J Aust; 2012 Aug; 197(3):145. PubMed ID: 22860781
    [No Abstract]   [Full Text] [Related]  

  • 30. [Gammahydroxybutyrate must remain available for patients with narcolepsy].
    Lammers GJ; van Dijk JG; Ferrari MD; van Gerven JM; Declerck AC; Troost J
    Ned Tijdschr Geneeskd; 1999 Oct; 143(41):2062-3. PubMed ID: 10560549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylphenidate: abuse and addiction.
    Prescrire Int; 2012 Oct; 21(131):241. PubMed ID: 23189380
    [No Abstract]   [Full Text] [Related]  

  • 32. 'Uppers' keep going up.
    Ghodse H
    Br J Psychiatry; 2007 Oct; 191():279-81. PubMed ID: 17906235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sociological approaches to the study of drug use and drug policy.
    Stevens A
    Int J Drug Policy; 2011 Nov; 22(6):399-403. PubMed ID: 22078055
    [No Abstract]   [Full Text] [Related]  

  • 34. Attention deficit hyperactivity disorder in prison.
    Ghanizadeh A; Akhondzadeh S
    J Am Acad Psychiatry Law; 2009; 37(2):278. PubMed ID: 19535565
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.
    Jain R; Stark JG
    Postgrad Med; 2016 Sep; 128(7):672-81. PubMed ID: 27467139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methylphenidate of retard forms in children and adolescents with ADHD - an overview].
    Pelz R; Banaschewski T; Becker K
    Klin Padiatr; 2008; 220(2):93-100. PubMed ID: 18157763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The consumable vice: caffeine, public health, and the law.
    Hodge JG; Scanlon M; Corbe A; Sorensen A
    J Contemp Health Law Policy; 2010; 27(1):76-119. PubMed ID: 21322400
    [No Abstract]   [Full Text] [Related]  

  • 39. Governing through problems: the formulation of policy on amphetamine-type stimulants (ATS) in Australia.
    Fraser S; Moore D
    Int J Drug Policy; 2011 Nov; 22(6):498-506. PubMed ID: 22054738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
    Kollins SH
    J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.